A fermented substance from Aspergillus phoenicis reduces liver fibrosis induced by carbon tetrachloride in rats.
The purpose of this study was to investigate the hepatoprotective effects of a fermented substance from Aspergillus phoenicis (FSAP) on chronic liver injuries induced by carbon tetrachloride (CCl(4)) in rats. CCl(4) (20%; 0.2 ml/100 g body weight) was given twice a week for 9 weeks, and the rats received FSAP throughout the whole experimental period. Plasma ALT and AST, spleen weight, and hepatic levels of lipid peroxidation and hydroxyproline were significantly lower in the rats treated with FSAP as compared to CCl(4) only. Liver pathology in the FSAP-treated rats was also improved. Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) analysis showed that FSAP treatment increased the expression of matrix metalloproteinase 13 and decreased the expression of methionine adenosyltransferase 2A, collagen (alpha1)(I), collagen (alpha1)(III), transforming growth factor-beta1, and tissue inhibitor of metalloproteinase 1. These results clearly indicate that FSAP partially reduced the liver fibrosis in rats induced by CCl(4).
Fang
Hsun-Lang
HL
Graduate Institute of Chinese Pharmaceutical Science, Collage of Pharmacy, China Medical University, Taichung, Taiwan.
Lai
Jinn-Jsyy
JJ
Lin
Wei-Lii
WL
Lin
Wen-Chuan
WC
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001230:Aspergillus / Q000737:chemistry*; D002251:Carbon Tetrachloride / Q000633:toxicity; D024042:Collagen Type I / Q000378:metabolism; D024061:Collagen Type III / Q000378:metabolism; D005285:Fermentation; D006909:Hydroxyproline / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D053509:Matrix Metalloproteinase 13 / Q000378:metabolism; D008716:Methionine Adenosyltransferase / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D020011:Protective Agents / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012709:Serum Albumin / Q000032:analysis; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
D024042:Collagen Type I; D024061:Collagen Type III; D020011:Protective Agents; D012333:RNA, Messenger; D012709:Serum Albumin; D019715:Tissue Inhibitor of Metalloproteinase-1; D053773:Transforming Growth Factor beta1; D008315:Malondialdehyde; D002251:Carbon Tetrachloride; C512846:Mat2a protein, rat; D008716:Methionine Adenosyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D053509:Matrix Metalloproteinase 13; C507083:Mmp13 protein, rat; D006909:Hydroxyproline